Abstract

Osteonecrosis of the jaw (ONJ) is a site specific osseous pathology, characterized by chronic exposed bone in the mouth, which needs to be reinforced periodically within the medical literature. ONJ is a clinical entity with many possible aetiologies and its pathogenesis is not well understood. The risk factors for ONJ include bisphosphonates treatments, head and neck radiotherapy, dental procedures involving bone surgery, and trauma. Management of ONJ has centred on efforts to eliminate or reduce severity of symptoms, to slow or prevent the progression of disease, and to eradicate diseased bone. This case describes a rare case of ONJ in a 64-year-old Caucasian male diagnosed with multiple myeloma stage III. The lesion was related to a traumatic injury during mastication. Eighteen months ago in the same area the molar 37 was extracted, achieving a complete satisfactory healing, when only 2 doses of zoledronic acid had been administered. Actinomyces bacterial aggregates were also identified in the microscopic analysis. The management of this osteonecrotic lesion included antibiotic treatment and chlorhexidine topical gel administration. The evolution was monitored every two weeks until patient's death. The authors provide a discussion of the etiology, pathogenesis, diagnosis, and management. This case report may shed light on the controversies about concomitant factors and mechanisms inducing ONJ.

Highlights

  • Osteonecrosis of the jaw (ONJ) is a site specific osseous pathology, characterized by exposed bone in the mouth that does not heal with 6 to 8 weeks of therapy

  • It is very likely that ONJ is a clinical entity with many possible aetiologies and its pathogenesis is not well understood [1]

  • The objective of this paper is to report an unusual clinical case of ONJ in a patient with multiple myeloma-related bone disease

Read more

Summary

Introduction

Osteonecrosis of the jaw (ONJ) is a site specific osseous pathology, characterized by exposed bone in the mouth that does not heal with 6 to 8 weeks of therapy. ONJ has been reported in patients with a variety of tumour types, including multiple myeloma. These patients are receiving long-term chemotherapy and many short-term intermittent corticosteroid therapies with concomitant bisphosphonate therapy for cancer and symptom management [1]. Cancer patients treated with intravenous bisphosphonates account for the majority of bisphosphonate-related ONJ cases, individuals taking oral formulations, most often for osteoporosis, may be affected [8]. These lesions typically become symptomatic in case of secondary infections, trauma to adjacent soft tissues, or other. The objective of this paper is to report an unusual clinical case of ONJ in a patient with multiple myeloma-related bone disease

Case Report
Discussion
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call